The case
The strong profitability of global pharmaceutical companies, including MSD (Merck Sharp & Dohme), generates billions of Swiss francs in tax revenue, making the sector one of Switzerland’s largest contributors to public finances.
Source: SonntagsZeitung, 28 June 2026; also reported by economiesuisse and other media.
The commentary
According to the articles, 0.5 % of the companies account for nearly three-quarters of corporate income tax revenues, i.e. the equivalent to approximately CHF 30 – 36 billion in total annually.
At the same time, this success also creates risks. As much of the industry’s revenue is earned in the United States, Swiss-based pharmaceutical companies are increasingly exposed to US healthcare policy. Pressure to lower drug prices and expand manufacturing and research in the USA could gradually shift investment, jobs as well as value creation away from Switzerland.
The articles conclude that while Switzerland is benefitting greatly from the pharmaceutical sector, its reliance on a single industry and the US market highlights the importance of maintaining an attractive environment for research, innovation and global business.









